Geron ACTC AAPL all down

No news on Geron, ACTC and BTX. All down a little. Geron down 3 cents at $1.41. ACTC closed at 0.0613, we'll see 5 cent soon with no news. BTX down 5 cents at $3.59. AAPL down $4.08 at $585.28. AAPL will soon be selling new iPhones in China, should move price up, if they sell like hotcakes................................................... ................................................................................................................................................................................Good luck in this rigged casino,

BioTime up

I don't get why BioTime is moving up. Maybe the Geron deal is a deal for BioTome. The cost to bring the stem cell program to Phase 3 would be around $200-300 million give or take $100 million. Bio Time does not have it. BTX closed up at $3.64 on avg volume................................................................................ ...................................................................................... Geron up 2 cent at $1.44 on light volume. I've bought back most of my $2 Mar 13 calls. Thinking good news early in Dec 5-7. ............................................... ............................................................................................................................................................................. ACTC down a litte to close at 0.0621. Need good results on Phase 1/2.................. .............................................................................................................................................................................. AAPL slowly moving up closed at $589.36. Need $100 more for my calls, but will sell some at $625......................................................................... Good luck in this rigged casino.

ACTC Announces Completion of Higher Dosage

ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical Trials Three Patients with Forms of Macular Degeneration Injected with 100,000 hESC-Derived RPE Cells, Successfully Completing Second Cohort...................................... ......................................................................................................................................................................................................................................................................Great news for ACTC closed at 0.0622. Need results and a partner with lots of money. . ......................................................................................................................................................................................................................................................................Geron closed up 4 cent at $1.42 on light volume. I would think we should run up more before results of Phase 2 trials............................................... ............................................................................................................................................................................. BTX closed up 6 cents on light volume. It's hard to believe this company will get Geron's stem cell property for pennies on the dollar. Soon I will be adding BioTime as the future of bio tech.............................................................. Good luck in this rigged casino,

HP was duped in Autonomy Deal

Not going to say much about Geron, ACTC and AAPL today. Let's look at this rigged casino. HP paid 10 billion dollars about a year ago for Autonomy and guess what the company is worth only 1 billion dollars. You would think the people running HP would know what the value of the company was. You would think someone at Autonomy would know someone was cooking the books. After 30 years of investing, I can say that was my biggest mistake "investing" [and I've made many many many big mistakes]. You should only invest if you have inside infor. Because the market is a rigged casino and the average investor doesn't stand a chance................................................ Good luck in this rigged casino.

BTX up big, Geron up

The market must like BTX's Stem Cell deal with Geron. BTX is up 46 cents or 15% at $3.51 on 389,396 shares the three month avg. is 82,711 shares. ............................. ..................................................................................................................................................................................................................................................................... Geron closed up 7 cents at $1.32 on only 556,757 shares. .............................. ..................................................................................................................................................................................ACTC closed at 0.064, volume was 5.4 million shares. If the reverse split does not happen soon and there is no good news, we go to 5 cents................................ ..................................................................................................................................................................................................................................................................... AAPL moved up big time to close at $565.73, need a $100 run just to break even on my calls............................................................................... Good luck in this rigged casino,

BioTime like deal Geron not so much

Geron was up 4 cents and closed at $1.25 on only 537,556 shares the 3 month avg volume is 1.7 million shares. BioTime was up 8 cents on 141,710 shares the 3 month avg volume is 82,265 shares. I'm hoping for a better deal. Geron spent about $500,000,000 on there stem cell program. They are getting maybe $40 million, what a deal,,,,for BioTime. ............................................................................................................................................................................................................................................................ ACTC closed at 0.064 on 6.3 million shares the three month avg volume is 5.8 million sshares. Need good news................................................... .............................................................................................................................................................................. AAPL I think hit bottom today and closed at $527.68 on 44.8 million shares. The three month avg. is 19 million shares. .................................................... ..................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

Geron Announces Non-Binding Letter of intent with BTX

MENLO PARK, Calif., November 15, 2012 -- Geron Corporation (Nasdaq: GERN) today announced that the company has entered into a non-binding letter of intent (LOI) with BioTime, Inc. (NYSE: BTX) and BioTime's recently formed subsidiary, BioTime Acquisition Corporation (BAC). The LOI contains broad terms of a potential transaction through which Geron would contribute to BAC its intellectual property and other assets related to Geron's discontinued human embryonic stem cell programs. BioTime would contribute to BAC $5 million in cash, $30 million of BioTime common shares, warrants to purchase eight (8) million shares of BioTime at a pre-specified price (the "BioTime Warrants"), rights to use certain human embryonic stem cell lines, and minority stakes in two of BioTime's subsidiaries. Following consummation of the potential transaction, Geron stockholders would receive shares representing 21.4% of the common stock of BAC as well as warrants to purchase eight (8) million shares of BioTime common stock at a pre-specified price. BioTime would own approximately 71.6%, and a private investor would own approximately 7.0% of the outstanding BAC common stock for an additional $5 million investment. BioTime would also receive warrants that would enable it to increase its ownership in BAC by approximately 2%, which would dilute the Geron stockholders' ownership in BAC to 19.2%. BAC would also be committed to pay to Geron royalties on the sale of products that are commercialized in reliance upon Geron patents acquired by BAC. The LOI and its broad terms are not binding. Consummation of the transaction is necessarily subject to entering into a definitive agreement between the parties containing specific signing and closing terms and conditions yet to be negotiated. Stifel Nicolaus Weisel is acting as financial advisor and Weil, Gotshal & Manges LLP is acting as legal counsel to Geron in connection with the divestiture of Geron's stem cell assets. What does Geron shareholders get dollar wish next to nothing. When BTX made there move there share pric was over $4 NOW IT'S UNDER $3. But a little money is better then nothing and more important the science will go forward. Geron closed at $1.21 on only 402,999 shares.......................................... ..................................................................................................................................................................................................................................................................... ACTC down 0.0648 on 5.5 million shares................................................ .............................................................................................................................................................................. AAPL is killing me at may go under $500 which is just crazy. Closed at $525.62......... Good luck in this rigged casino,

Geron and ACTC down

AAPL up 7 whole cent to $542.90 on 19 million shares. The three month avg volume is 18.5 million shares. The fiscal cliff is holding the market back. The longer it takes to fix the lower we go. If they can fix it fast, up up up we go. .................................................................................... ACTC down under 7 cents at 0.0685 on 5.8 million shares. Waiting for results on Phase 1/2 trials......................................................................... ..................................................................................................................................................................................................................................................................... Geron down to $1.24 on only 635,399 shares. Around Dec 5th Chip will tell us about all the Phase two trials. If it's good we run up to $2-$3, if bad, it's over............. Good luck in this rigged casino,

Depressing AAPL and Geron down, ACTC up on good news

What a depressing market. AAPL down down down to $537.75 on alot of volume 37.7 million shares. The three month avg. is 17.6 million shares. AAPL is still the best company out there, for now, makes you think what in the world is going on. ..................................................................................................................................................................................................................................................................... Geron down to $1.28 I can only hope Dec. will being good results the the last 4 trials. If I will be sitting here crying........................................ ..................................................................................................................................................................................................................................................................... ACTC had good news on was up a little at 0.072. Advanced Cell Tech. announces interim data from its three ongoing macular degeneration trials; no adverse safety issues relating to the transplanted cells have been observed (ACTC) 0.07 +0.00 : Co announced that its upcoming conference call on its third quarter financial results will also provide some representative examples of data being collected from patients in its clinical trials for forms of macular degeneration. The Company has treated 13 patients thus far in its three ongoing trials for dry age-related macular degeneration (dry AMD) and Stargardt's Disease (SMD) using human embryonic stem cell (hESC)-derived retinal pigment epithelial cells. The first two trials were initiated in July of 2011. Across the various clinical trial sites, with regular patient follow-up, no adverse safety issues relating to the transplanted cells have been observed. At up to 16 months following treatment, no hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection were observed in any of the 13 patients at any time. At a recent meeting of the various U.S. and U.K. surgeons leading the clinical trials, the Company and surgeons reviewed the data from various patients and discussed next steps and strategies for the existing trials and designs for future phase II and III studies..............................................I still have a good feeling about this company. It's a very, very long shot.............................................. .............................................................................................................................................................................. Good luck in this rigged casino,

Geron and AAPL killing me

Geron down 6 cent to close at $1.31 on only 453,489 the ten day avg is 789,925 shares. Waited for Phase two trial results in early Dec. Again this will make or break this company............................................................................... ..................................................................................................................................................................................................................................................................... AAPL is a big disappointment, didn't hold $600 and may go to $550. Closed down a little at $582.85. Christmas may save AAPL............................................. ..................................................................................................................................................................................................................................................................... ACTC up over 7 cents to closed at 0.0727 on 5.8 million shares the ten day avg is 4.4 million shares. Still feel this company will make it big, with little luck............ ..................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

Geron good article by Ivan Deryigin

I could have sold my shares in September and walked away with profits of almost 70%, and that would have been the end of it. However, I chose not to do that. And the reason is simple. This was, and is, an investment only for risk tolerant investors, who have room for speculation in their portfolios. And I consider this investment to be, at the moment, a speculative one. When I wrote my original article, I stated that Geron has the potential to change the way that cancer is treated, due to its focus on telomerase inhibition and brain tumors. I stand by that opinion. The failure of imetelstat in solid tumors has not affected the company`s hematologic trials, nor has it affected the development of GRN-1005, which has the potential to create a truly effective treatment for brain metastases, something that has eluded cancer researchers and pharmaceutical companies for years, due to the blood-brain barrier and the difficulty of getting cancer medications across it. While Geron does have the potential to change the way that cancer is treated, the path ahead is an uncertain one, and this stock is not meant for all investors. But, for investors who are willing to take the risk, Geron continues to offer the opportunity for profits, with the next catalyst just a month away. Above is a small part of the article. This is the guy who pumped it up in Sept. up to $2.99. I hope he can do it again. With good results we should go to $3, with poor results it's all over. Geron is up 7 cents on this article. Good luck in this rigged casino,

All down ACTC AAPL Geron

Bad day, AAPL down big closing at $576.80, ACTC down under 7 cents, and Geron down 7 cents at $1.32......., ............................................................... ............................................................................................................................................................................. Nothing good will happen till after the election and the fiscal cliff is fixed......... .................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

Geron up, ACTC up and AAPL up

Geron was up 6 cents on very light volume only 560,143 shares. The three month avg is 1.6 million shares. Remember Chip said in a few days Geron will file a SEC 10-K report on the BioTime deal. BioTime was down 14 cents to $3.67 just a week ago it was over $4. The volume was 2xs the normal. Based on BioTime's price drop and volume I'm thinking Geron may take the deal, I hope GE makes a offer. Time was tell. ..................................................................................................................................................................................................................................................................... ACTC closed at 7 cents on avg. volume. Still waiting on results of Phase 1/2 trials should be in 3 to 6 months. .................................................................................................................................................................................................................................................................... AAPL up just a little to close at $596.54. Hoping people buy 10 million mini Ipods for the holidays......................................................................... ..............................................................................................................................................................................Good luck in this rigged casino,

Geron Earning Call

Well I read the earnings call and learned next to nothing. Upset about no infor on the stell cell deal. Chip did say in a few days will file a SEC 10-K about the BioTime deal. Chip said reports of Phase 2 trials will be coming in Dec. Again this will make or break Geron. I have no good or bad feeling about up coming reports. Good luck in this rigged casino,

ACTC gets OK for 2nd Patient Cohort in Trials for Dry AMD

Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company's three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of two additional patients with dry age-related macular degeneration (dry AMD). ACT will screen and enroll the second and third patients of the three-patient second cohort in the trial. Per trial protocol, each patient will be injected with 100,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. "Dry AMD represents one of the largest unmet medical needs in the world, and we are thrilled to be making steady progress in our clinical trial for this condition," commented Gary Rabin, ACT's chairman and CEO. "We are well on our way to the halfway point of all three of our clinical trials. We also recently secured DSMB approval to complete the second cohort of our two trials for Stargardt's Macular Dystrophy." ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration, dry AMD and Stargardt's Macular Dystrophy (SMD). Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format, from 50,000 to 200,000 hESC-derived RPE cells. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or SMD at 12 months, the study's primary endpoint. "This authorization to treat the next two patients in the second, higher-dosage cohort of our trial for dry AMD represents a notable milestone for our clinical programs," commented Robert Lanza, M.D., ACT's chief scientific officer. "We look forward to treating these two patients and moving on to the third cohort in good time." Good news trials moving forward. Good luck in this rigged casino,